Phathom Pharmaceuticals, Inc. - Common Stock (PHAT)

CUSIP: 71722W107

Q1 2020 13F Holders as of 31 Mar 2020

Holder snapshot 6 signals
Share change
+139,226
SEC-reported price per share
$25.82
Indexed holders
47
Value change
+$3,219,839
Number of buys
25
Number of sells
17
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
81,261,176

Security key

71722W107

Report period

Q1 2020

Indexed institutions

47

Top holders

10

Ownership snapshot

Top reported holders of PHAT - Phathom Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
FRAZIER MANAGEMENT LLC
Disclosed value leader
FRAZIER MANAGEMENT LLC
Comparable rows
0/15
Latest evidence
31 Dec 2019
13F Highest disclosed value: $226,832,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

FRAZIER MANAGEMENT LLC has the largest disclosed position value at $226.83M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens FRAZIER MANAGEMENT LLC's linked filing trail.
Disclosed position value Top 5
FRAZIER MANAGEMENT LLC $226.83M
RA CAPITAL MANAGEMENT, L.P. $113.56M
Invesco Ltd. $65.47M
Medicxi Ventures Management (Jers... $64.39M
Janus Henderson Group Ltd. $43.59M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
FRAZIER MANAGEMENT LLC
13F
Company
13F
—
denominator unverified
$226,832,000
7,284,269 shares
— 31 Dec 2019
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
—
denominator unverified
$113,562,000
3,646,808 shares
— 31 Dec 2019
Invesco Ltd.
13F
Company
13F
—
denominator unverified
$65,466,000
2,102,303 shares
— 31 Dec 2019
Medicxi Ventures Management (Jersey) Ltd
13F
Company
13F
—
denominator unverified
$64,393,000
2,067,861 shares
— 31 Dec 2019
Janus Henderson Group Ltd.
13F
Company
13F
—
denominator unverified
$43,589,000
1,467,462 shares
— 31 Dec 2019
Abingworth LLP
13F
Company
13F
—
denominator unverified
$37,430,000
1,203,135 shares
— 31 Dec 2019
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2020

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
47
Shares
21,949,381
Indexed holders
47
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2020 vs Q4 2019 Across Filers

Q4 2019 indexed holders
40
Q1 2020 indexed holders
47
Indexed holder difference
7
Investor Q4 2019 Shares Q1 2020 Shares Share Diff Share Chg % Q4 2019 value Q1 2020 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .